Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

37.35
Delayed Data
As of 4:00pm ET
 -0.37 / -0.98%
Today’s Change
33.60
Today|||52-Week Range
50.40
-2.10%
Year-to-Date
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
Apr 27 / Zacks.com - Paid Partner Content
K-Mart to Sell Cheaper EpiPen Alternative
Apr 25 / TheStreet.com - Paid Partner Content
iAB Financial Bank Buys VF, Vanguard Large-Cap ETF - DNQ, Starbucks, Sells Ventas, Ta...
Apr 27 / GuruFocus News - Paid Partner Content
Sanofi Sues Mylan Over EpiPen Practices
Apr 24 / TheStreet.com - Paid Partner Content
Glaxo Stock Slumps as Investors Eye Advair Generics
Apr 26 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close37.72
Today’s open37.74
Day’s range37.12 - 37.83
Volume3,499,415
Average volume (3 months)5,498,599
Market cap$20.2B
Dividend yield--
Data as of 4:00pm ET, 04/28/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)+8.59%
Earnings growth (next 5 years)+4.40%
Revenue growth (last year)+17.44%
P/E ratio16.1
Price/Sales1.79
Price/Book1.82

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-0.42-0.44%
INCYIncyte Corp+0.11+0.09%
ZTSZoetis Inc-0.35-0.62%
ALXNAlexion Pharmaceutic...+0.87+0.69%
Data as of 4:14pm ET, 04/28/2017

Financials

Next reporting dateMay 10, 2017
EPS forecast (this quarter)$0.95
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts